



**Item 8.01 Other Events**

On September 17, 2007, Neurologix, Inc. (the "Company") approved a prearranged stock sales plan (the "Sales Plan") entered into by ATEC Trust, as seller, and Axiom Capital Management Inc., as broker. The Sales Plan is intended to qualify under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, and provides for the sale of up to 10,000 shares of the Company's common stock every calendar month provided that the per share sale price is at or above \$1.05. The Sales Plan will terminate, among other reasons, when sales under the Sales Plan result in net proceeds of \$340,000, but, in no event, later than September 30, 2009. The Sales Plan is in compliance with the Company's insider trading policies.

The foregoing description of the Sales Plan is not complete and is qualified in its entirety by reference to the Sales Plan, which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

99.1 Rule 10b5-1 Sales Plan executed by ATEC Trust, as seller, and Axiom Capital Management Inc., as broker.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto, duly authorized.

**NEUROLOGIX, INC.**

Date: September 21, 2007

By: /s/ Marc L. Panoff

Name: Marc L. Panoff

Title: Chief Financial Officer, Secretary and Treasurer